Burden of Disease of Breast Cancer in Italy: A Real-World Data Analysis

F. S. Mennini, A. Marcellusi, P. Sciattella, M. Scortichini, Angela Ragonese (), F. Cattel, R. D’Antona, L. Mastro, S. Gori, G. Perrone, R. Migliorini and M. Trabucco Aurilio
Additional contact information
F. S. Mennini: University of Rome “Tor Vergata”
A. Marcellusi: University of Rome “Tor Vergata”
P. Sciattella: University of Rome “Tor Vergata”
M. Scortichini: University of Rome “Tor Vergata”
Angela Ragonese: University of Rome “Tor Vergata”
F. Cattel: Direttore della Farmacia Ospedaliera della Azienda Ospedaliero-Universitaria della Città della Salute e della Scienza di Torino
R. D’Antona: Europa Donna Italia
L. Mastro: IRCCS Ospedale Policlinico San Martino Università degli Studi di Genova
S. Gori: Oncologico IRCCS Ospedale Sacro Cuore Don Calabria, Negrar di Valpolicella
G. Perrone: Università Campus Bio-Medico di Roma
R. Migliorini: Coordinamento Generale Medico-Legale, Istituto Nazionale di Previdenza Sociale (INPS)
M. Trabucco Aurilio: Università del Molise

PharmacoEconomics - Open, 2025, vol. 9, issue 2, No 9, 283-290

Abstract: Abstract Background Breast cancer (BC) constitutes a significant public health challenge in Italy, with a considerable impact on healthcare resources and societal costs. Despite advancements in diagnostics and therapies, the economic burden of BC remains substantial, necessitating a comprehensive evaluation to inform healthcare policy and resource allocation. The aim of this study is to estimate both direct health costs and social security costs related to BC. Methods This study utilized real-world data from the Italian Health Information System (HIS) and Local Health Unit (LHU) Umbria 2 HIS databases spanning 2010–2019. Direct health costs, encompassing hospitalizations, outpatient visits, and drug prescriptions, were assessed alongside social security costs associated with BC-related work inability. Statistical analyses and probabilistic models were employed to estimate costs and evaluate trends over time. Results The analysis revealed an annual cost of €273 million for hospital admissions related to BC in Italy, with metastatic BC (MBC) incurring the highest average annual cost per patient (€5018). When outpatient visits and drug consumption were incorporated, the mean annual cost per patient in LHU Umbria 2 rose to €11,380 for MBC. Social security costs, predominantly comprising disability benefits (DBs), totaled €579 million annually. Overall, the study estimated the total annual economic impact of BC in Italy to exceed €1 billion, with social costs representing 50.4% of the total burden. Conclusions This comprehensive assessment underscores the substantial economic strain imposed by BC in Italy and highlights the need for early detection and intervention strategies to mitigate costs and enhance patient outcomes. These findings offer valuable insights into the economic landscape of BC, guiding policy decisions and resource allocation efforts aimed at optimizing BC management and alleviating its societal burden.

Date: 2025
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s41669-024-00543-1 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:pharmo:v:9:y:2025:i:2:d:10.1007_s41669-024-00543-1

Ordering information: This journal article can be ordered from
http://www.springer.com/adis/journal/41669

DOI: 10.1007/s41669-024-00543-1

Access Statistics for this article

PharmacoEconomics - Open is currently edited by Timothy Wrightson and Christopher Carswell

More articles in PharmacoEconomics - Open from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().